Moreover, a preclinical study of tiragolumab, an Fc-competent anti-TIGIT antibody, demonstrated that it remodeled the tumor microenvironment by engaging IgG Fc receptors in an animal model, highlighting the potential clinical impact of Fc portion design on clinical outcomes [23]. The gene discussed is TIGIT; the disease is neoplasm.